2215 related articles for article (PubMed ID: 32198291)
1. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
Zhang L; Lin D; Sun X; Curth U; Drosten C; Sauerhering L; Becker S; Rox K; Hilgenfeld R
Science; 2020 Apr; 368(6489):409-412. PubMed ID: 32198291
[TBL] [Abstract][Full Text] [Related]
2. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
4. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
[TBL] [Abstract][Full Text] [Related]
5. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
6. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
7. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
[TBL] [Abstract][Full Text] [Related]
9. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
10. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
[TBL] [Abstract][Full Text] [Related]
11. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
12. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M
Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D
Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708
[TBL] [Abstract][Full Text] [Related]
13. Structural plasticity of SARS-CoV-2 3CL M
Kneller DW; Phillips G; O'Neill HM; Jedrzejczak R; Stols L; Langan P; Joachimiak A; Coates L; Kovalevsky A
Nat Commun; 2020 Jun; 11(1):3202. PubMed ID: 32581217
[TBL] [Abstract][Full Text] [Related]
14. Structure of M
Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
[TBL] [Abstract][Full Text] [Related]
15. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
16. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.
Cooper MS; Zhang L; Ibrahim M; Zhang K; Sun X; Röske J; Göhl M; Brönstrup M; Cowell JK; Sauerhering L; Becker S; Vangeel L; Jochmans D; Neyts J; Rox K; Marsh GP; Maple HJ; Hilgenfeld R
J Med Chem; 2022 Oct; 65(19):13328-13342. PubMed ID: 36179320
[TBL] [Abstract][Full Text] [Related]
17. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel
Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509
[TBL] [Abstract][Full Text] [Related]
18. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
19. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
20. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
